Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors

1. A polymorphic form of a compound of Formula IA:

wherein the polymorphic form is a hydrate selected from the group consisting of Form I, Form II, Form XIII, Form XV, Form XVI, and Form XVIII.

2. The polymorphic form of claim 1 , wherein the polymorphic form is Form I;

wherein Form I is characterized by a powder X-ray diffraction pattern comprising characteristic peaks (°2θ) at 6.6°±0.2°2θ, 17.1°±0.2°2θ, and 21.3°±0.2°2θ.

3. The polymorphic form of claim 2 , wherein the polymorphic form is further characterized by a powder X-ray diffraction pattern comprising at least one additional characteristic peak (°2θ) selected from the group consisting of 14.1°±0.2°2θ, 14.8°±0.2°2θ, 16.0°±0.2°2θ, 22.2°±0.2°2θ, and 24.3°±0.2°2θ.

4. The polymorphic form of claim 1 , wherein the polymorphic form is Form II;

wherein Form II is characterized by a powder X-ray diffraction pattern comprising characteristic peaks (°2θ) at 14.8°±0.2°2θ, 17.4°±0.2°2θ, and 20.1°±0.2°2θ.

5. The polymorphic form of claim 4 , wherein the polymorphic form is further characterized by a powder X-ray diffraction pattern comprising at least one additional characteristic peak (°2θ) selected from the group consisting of 5.9°±0.2°2θ, 7.9°±0.2°2θ, 13.6°±0.2°2θ, 20.6°±0.2°2θ, and 26.5°±0.2°2θ.

6. The polymorphic form of claim 1 , wherein the polymorphic form is Form XIII;

wherein Form XIII is characterized by a powder X-ray diffraction pattern comprising characteristic peaks (°2θ) at 11.6°±0.2°2θ, 17.4°±0.2°2θ, and 19.5°±0.2°2θ.

7. The polymorphic form of claim 6 , wherein the polymorphic form is further characterized by a powder X-ray diffraction pattern comprising at least one additional characteristic peak (°2θ) selected from the group consisting of 15.4°±0.2°2θ, 21.3°±0.2°2θ, 21.8°±0.2°2θ, and 26.8°±0.2°2θ.

8. The polymorphic form of claim 1 , wherein the polymorphic form is Form XV;

wherein Form XV is characterized by a powder X-ray diffraction pattern comprising characteristic peaks (°2θ) at 20.6°±0.2°2θ, 22.0°±0.2°2θ, and 25.7°±0.2°2θ.

9. The polymorphic form of claim 8 , wherein the polymorphic form is further characterized by a powder X-ray diffraction pattern comprising at least one additional characteristic peak (°2θ) selected from the group consisting of 7.0°±0.2°2θ, 13.2°±0.2°2θ, 15.3°±0.2°2θ, 19.6°±0.2°2θ, and 26.7°±0.2°2θ.

10. The polymorphic form of claim 1 , wherein the polymorphic form is Form XVI;

wherein Form XVI is characterized by a powder X-ray diffraction pattern comprising characteristic peaks (°2θ) at 7.8°±0.2°2θ, 19.8°±0.2°2θ, and 22.2°±0.2°2θ.

11. The polymorphic form of claim 10 , wherein the polymorphic form is further characterized by a powder X-ray diffraction pattern comprising at least one additional characteristic peak (°2θ) selected from the group consisting of 5.0°±0.2°2θ, 14.8°±0.2°2θ, 17.3°±0.2°2θ, 17.8°±0.2°2θ, and 26.0°±0.2°2θ.

12. The polymorphic form of claim 1 , wherein the polymorphic form is Form XVIII;

wherein Form XVIII is characterized by a powder X-ray diffraction pattern comprising characteristic peaks (°2θ) at 4.5°±0.2°2θ, 8.9°±0.2°2θ, and 22.1°±0.2°2θ.

13. The polymorphic form of claim 12 , wherein the polymorphic form is further characterized by a powder X-ray diffraction pattern comprising at least one additional characteristic peak (°2θ) selected from the group consisting of 13.3°±0.2°2θ, 18.0°±0.2°2θ, 24.7°±0.2°2θ, 27.2°±0.2°2θ, and 31.6°±0.2°2θ.

14. A method for inhibiting spleen tyrosine kinase activity in a human in need thereof, wherein the method comprises administering to the human the polymorphic form of claim 1 .

15. The method of claim 14 , wherein the human has a condition selected from the group consisting of an autoimmune disease, a cancer, and an inflammatory disease.

16. The method of claim 15 , wherein the autoimmune disease, cancer, or inflammatory disease is selected from the group consisting of acute graft-versus-host disease, an acute inflammatory reaction, acute lymphocytic leukemia, acute myeloid leukemia, Addison's disease, adult respiratory distress syndrome, Alzheimer's disease, asthma, atherosclerosis, an autoimmune hemolytic state, an autoimmune thrombocytopenic state, B-cell acute lymphoblastic leukemia, B-cell lymphoma, Burkitt lymphoma, chronic graft-versus-host disease, chronic idiopathic thrombocytopenic purpura, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic obstructive pulmonary disease, Crohn's disease, dermatomyositis, diabetes, follicular lymphoma, glomerulonephritis, Goodpasture's syndrome, hyperacute rejection of a transplanted organ, irritable bowel syndrome, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, multiple sclerosis, myasthenia gravis, myelodysplastic syndrome, myeloproliferative disease, non-Hodgkin's lymphoma, Parkinson's disease, polycystic kidney disease, psoriasis, pulmonary hemorrhage, rheumatoid arthritis, scleroderma, septic shock, Sjogren's disease, small lymphocytic lymphoma, systemic lupus erythematosus, T-cell acute lymphoblastic leukemia, T-cell lymphoma, tissue graft rejection, ulcerative colitis, vasculitis, and Waldestrom's macroglobulinemia.

17. The method of claim 16 , wherein the acute inflammatory reaction is appendicitis, cholocystitis, dermatitis, encephalitis, enteritis, gastritis, gingivitis, hepatitis, inflammatory bowel disease, inflammatory pelvic disease, meningitis, myocarditis, myositis, nephritis, osteomyelitis, pancreatitis, pneumonitis, skin sunburn, sinusitis, urethritis, or uveitis.

18. The method of claim 16 , wherein the B-cell lymphoma is diffuse large B-cell lymphoma.

19. The method of claim 16 , wherein the non-Hodgkin's lymphoma is indolent non-Hodgkin's lymphoma.

20. The method of claim 19 , wherein the indolent non-Hodgkin's lymphoma is refractory indolent non-Hodgkin's lymphoma.

21. The method of claim 16 , wherein the vasculitis is anti-neutrophil cytoplasmic antibody associated vasculitis.